← Back to Search

Durvalumab for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Led By Catherine Shu, MD
Research Sponsored by Catherine Shu
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

Study Summary

This trial will test whether it is safe to give patients durvalumab and tremelimumab, immunotherapies that activate the body's own immune system to fight cancer, after they have completed standard treatment for NSCLC and when they have detectable ctDNA in their blood.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of evaluable patients enrolled
Secondary outcome measures
Adverse events rate
Disease free survival
Overall survival
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: durvalumab+ tremelimumabExperimental Treatment2 Interventions
durvalumab will be administered Q4weeks and tremelimumab will be administered Q8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Durvalumab
2017
Completed Phase 2
~3870
Tremelimumab
2017
Completed Phase 2
~3380

Find a Location

Who is running the clinical trial?

Catherine ShuLead Sponsor
1 Previous Clinical Trials
2 Total Patients Enrolled
Catherine Shu, MDPrincipal InvestigatorColumbia University
2 Previous Clinical Trials
41 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other medical studies have included Durvalumab as a treatment?

"There are a total of 345 clinical studies currently underway that focus on Durvalumab. Out of those, 51 are Phase 3 trials. The majority of these trials take place in Cordoba, Texas; however, there are 13050 research sites for this drug around the world."

Answered by AI

What medical condition does Durvalumab target?

"Durvalumab is most frequently used to treat patients with stage three non-small cell lung cancer that cannot be removed surgically. This immunotherapy drug can also help those suffering from metastatic ureter urothelial carcinoma or advance directives."

Answered by AI

How many individuals are enrolled in this experiment?

"Currently, this clinical trial is not recruiting patients. The study was originally posted on December 1st, 2022 and was last edited on April 29th, 2022. For those looking for other studies, there are 2098 trials for lung cancer and 345 for Durvalumab that are actively enrolling participants."

Answered by AI

Does this study explore new territory?

"Durvalumab has been involved in 345 active clinical trials across 58 countries and 1325 cities. The first study occurred in 2007 and was sponsored by AstraZeneca. Only 37 patients were observed during the Phase 2 drug approval stage of this trial. In the 14 years since then, 123 more studies have taken place."

Answered by AI

Is Durvalumab a safe medication for human patients?

"Durvalumab has received a score of 2 due to the lack of efficacy data, although there have been Phase 2 clinical trials that suggest it is safe."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
Catherine Shu 2022. "Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04625699.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top